Terry Declue
Pediatric Endocrinology · Tampa, FLNPI 1962481127
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,879, more than ten times the $186 reported in 2019.
Across 300 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$729
- AbbVie$504
- Dexcom, Inc.$503
- Novo Nordisk$414
- Neurocrine Biosciences, Inc.$403
- Insulet Corporation$366
- plus $3K from 31 others
Across 9 payments — averaging $3105.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$28K
What the payments were for
- Food & beverage$6,33099%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 36 | $729 |
| AbbVie | 25 | $504 |
| Dexcom, Inc. | 25 | $503 |
| Novo Nordisk | 21 | $414 |
| Neurocrine Biosciences, Inc. | 16 | $403 |
| Insulet Corporation | 18 | $366 |
| Sanofi-aventis U.S. LLC | 14 | $338 |
| Eton Pharmaceuticals, Inc. | 3 | $281 |
| Tolmar Pharmaceuticals, Inc. | 16 | $242 |
| Abbott | 13 | $224 |
| Pfizer | 12 | $223 |
| Azurity Pharmaceuticals, Inc. | 9 | $192 |
| BETA Bionics, Inc. | 8 | $189 |
| Tandem Diabetes Care, Inc. | 9 | $188 |
| Xeris Pharmaceuticals, Inc. | 10 | $179 |
| Lifescan, Inc. | 8 | $153 |
| Biomarin Pharmaceutical Inc. | 6 | $140 |
| Medtronic | 3 | $126 |
| Tolmar, Inc. | 6 | $124 |
| Endo USA, Inc. | 5 | $111 |
| Sequel Med Tech, LLC | 3 | $102 |
| Sanofi | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Endo Pharmaceuticals Inc. | 5 | $84 |
| Kyowa Kirin, Inc. | 3 | $63 |
| Zealand Pharma US, Inc. | 3 | $63 |
| Embecta Corp. | 2 | $42 |
| Rhythm Pharmaceuticals, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Soleno Therapeutics, Inc. | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| BD | 1 | $18 |
| PTC Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lupron Depot$121
- Alkindi$114
How this compares
$6,406 in reported general payments places this provider in the 70th percentile of 102 pediatric endocrinology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LevocarnitineLevocarnitine (With Sugar) | 25 | $4,600 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Tampa
- Henry RodriguezTampa$211K
- Dorothy ShulmanTampa$104K
- Danielle ReynoldsTampa$8K
- Grace DouganTampa$6K
- Tsu-Hui LinTampa$3K
- Joshua YangOrlando$846K
- Michael HallerGainesville$102K
- Alejandro DiazMiami$101K
- Samuel FreedmanPembroke Pines$71K
- Jennifer MillerGainesville$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.